Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TLC 388

Drug Profile

TLC 388

Alternative Names: Lipotecan; TLC-388; TLC388 HCl

Latest Information Update: 21 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiwan Liposome Company
  • Class Antineoplastics; Camptothecins
  • Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors; Hedgehog protein inhibitors; Hypoxia-inducible factor 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Rectal cancer
  • No development reported Solid tumours
  • Discontinued Renal cell carcinoma

Most Recent Events

  • 04 Nov 2018 Taiwan Liposome Company terminates a phase I/II trial for Hepatocellular carcinoma in Taiwan, as the study design could not support further development in this indication (IV) (NCT03035006)
  • 24 Jun 2018 Biomarkers information updated
  • 25 Jan 2017 Taiwan Liposome Company plans a phase I/II trial for liver cancer in Taiwan and China (IV) (NCT03035006)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top